The TB-500 reading shelf

The titles put pressure on the name

For the identity question, start with Ho and colleagues' TB-500 analysis in horse samples. It concerns the fragment itself. Read it alongside the actin-binding-domain peptide in diabetic and aged mice, the narrow experimental foothold for a smaller piece carrying repair activity.

The dystrophin-deficient mouse study is my choice for the word “recovery”: regenerating fibers increased, but significant strength improvement did not follow. The rat wound paper then earns its place by naming separate measurements rather than leaving “healing” undefined.

For human evidence, the intravenous safety study and ophthalmic corneal-healing paper concern full-length thymosin beta-4. The 2026 sports-medicine review addresses the wider unapproved-peptide problem. Those papers anchor the human question for me before the fragment receives any clinical credit.

FDA's safety-risk entry, Section 503A framework and advisory-committee record serve different purposes. The historical Category 2 description in the citation records the older safety decision; on FDA's page current as of April 22, 2026, the nomination appears in the withdrawn-request table. The legal-status essay preserves that distinction.